Ayman Grada News Today : Breaking News, Live Updates & Top Stories | Vimarsana

According to a study in JAMA Dermatology, the prescribing rates of spironolactone for acne in women rose about 300% from 2017 to 2020.

Yale researchers, using atomic-level Cryo-EM microscopy, have discovered how and why a particular antibiotic is superior to others as a treatment for acne.

Almirall is introducing Klisyri (tirbanibulin), for the topical treatment of actinic keratosis of the face and scalp. Klisyri is a novel, topical, first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile. AK is the second most common diagnosis made by dermatologists in the United States. It is estimated that more than 40 million Americans develop AKs each year. Ayman Grada, head of R&D and medical affairs at Almirall U.S. said that the...

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis -- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp -- Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1 -- In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significant...